Ethicon*, a trusted leader in advancing wound closure, announces the launch of STRATAFIX™ Spiral PDS Plus and STRATAFIX™ Spiral Monocryl Plus Knotless Tissue Control Devices. With the addition of these two new suture technologies to the STRATAFIX™ Family of Knotless Tissue Control Devices, Ethicon has established the most comprehensive and unmatched knotless suture offering available to surgeons in the U.S.
STRATAFIX™ Knotless Tissue Control Devices transforms the wound closure experience by providing unique advantages over traditional sutures. STRATAFIX™ sutures provide more strength and security, more consistency and more efficiency than traditional suturing. The portfolio of knotless sutures also enables surgeons to more easily manage tension and control tissue approximation with each pass during closure and eliminates the need to tie knots.
To view the multimedia release go to:
http://www.multivu.com/players/English/7889651-ethicon-new-stratafix-suture/
You stock your kitchen’s pantry shelves with quality food. Why would you skimp on the shelves of your bathroom cabinet? With cold and flu season upon us, it’s a great time to purge the medicine cabinet. Better to shop and prepare now than scramble when you are sick. Clean out clutter, get rid of anything that’s expired or you aren’t using, and stock up on the staples. A fresh start can make all the difference.
Well-known RN and health expert, Linda Ciampa has been helping families stay healthy for over a decade. On Wednesday, January 18th, Linda will be available for live interviews to share her best tips for preparing your medicine cabinet for the colder weather. She will also provide viewers with an easy-to-use option for keeping track of your family’s medical and fitness information.
Today, the newly-developed Body Volume Indicator (BVI)™ was revealed as a modern day measure of body composition and weight distribution following a 10-year collaboration with Mayo Clinic experts who led extensive research on fat distribution, the importance of fat assessment and the limitations of the current standard of Body Mass Index (BMI). In conjunction with the development of BVI, BVI America LLC, a subsidiary of 3D measurement pioneer Select Research, announced the launch of the revolutionary BVI Pro tablet application, which will provide an easily accessible and affordable means for the professional community to use the new BVI measurement in everyday clinical use to assess health risks.
The potential benefits of using Body Volume as a new indicator of risks were presented on April 27 by Mayo Clinic researchers, BVI America and the University of Westminster. It draws on 10 years of rigorous research, testing and validation using several potential Body Volume indices. Now BVI, calculated as a ratio between total volume and abdominal volume, can be used as a supplement to the current measurement standard of BMI, which is based solely on height and weight. BVI is considered to be a more precise means of estimating weight distribution and the fat around the organs, which is not visible to the human eye and can lead to serious health conditions, such as diabetes and heart disease. The medical and professional community at large is invited to contribute to the continued development of BVI by downloading and using the BVI Pro tablet application with their patients and clients; anonymous data collected will be analyzed by Mayo Clinic, whose research and validation of BVI will continue.
To view the multimedia release go to:
https://www.multivu.com/players/English/8093051-bvi-america-body-volume-app-health-fitness/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute in Boston; Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in New York; MD Anderson Cancer Center in Houston; Fondazione Centro San Raffaele in Milan; and South Australian Health & Medical Research Institute in Adelaide.
This $40.3 million investment, comprised of 75 new research grants in LLS’s portfolio of 300 projects, will fund a diverse array of research to find better treatments and cures for patients with leukemia, lymphoma, myeloma and other blood cancers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554855-lls-invests-millions-new-research-treatment-cures/
Allergan plc (NYSE:AGN), a global leader in eye care for nearly 70 years, today unveiled #EyePic, an exciting new online awareness campaign as part of the See America initiative to fight preventable blindness and visual impairment in the United States. #EyePic will use the power of social media to broaden awareness of preventable blindness, promote discussion around eye health and ultimately encourage all Americans to visit their eye doctors for comprehensive eye exams.
To view the multimedia release go to:
https://www.multivu.com/players/English/8134051-allergan-see-america-eyepic-campaign/
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will launch its latest advancement in comprehensive medication management, BD HealthSight™ platform for enterprise medication management, which offers a unique combination of connective technologies, analytics and expert services at this year's American Society of Health-System Pharmacists (ASHP) 2017 Midyear Meeting being held in Orlando from Dec. 3-7.
With direct medical costs associated with medication errors reaching $21 billion worldwide, innovative strategies must be developed to address the grand health challenges associated with medication management. BD has been evolving its focus to re-invent medication management with integration of the company’s technologies, analytics and expert services that aim to close the communication gaps across disparate solutions. The BD HealthSight platform connects systems and processes to help hospitals and health systems drive a safer, more efficient medication management process.
To view the multimedia release go to:
https://www.multivu.com/players/English/8198551-bd-healthsight-platform-ashp-2017/
West Pharmaceutical Services, Inc. (NYSE: WST) and HealthPrize Technologies, LLC, today announced the completion of the first two phases of their four-phase strategic collaboration. The companies are working to integrate HealthPrize’s Software-as-a-Service (SaaS) medication adherence and patient-engagement platform with West’s injectable drug delivery systems to provide an end-to-end connected health solution for pharmaceutical companies and the patients they serve. The combined offering will provide voluntary, electronically connected drug delivery systems that track when patients take their medication. The HealthPrize system engages and educates patients to increase adherence and medical literacy, rewarding interaction and compliance with prescribed treatment plans, and contributing to better health outcomes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7625851-west-pharma-healthprize-tech-collaboration/
The nation’s rate of preterm birth—the largest contributor to infant death in the United States -- increased again in 2016, after nearly a decade of decline, earning the nation a “C” grade on the latest March of Dimes Premature Birth Report Card.
The rate of preterm birth rose in states across the country for a second year in a row. More than 380,000 babies are born preterm in the U.S. each year, facing a greater likelihood of death before their first birthday, lifelong disabilities or chronic health conditions. An additional 8,000 babies were born prematurely in 2016 due to the increase in the preterm birth rate between 2015 and 2016, the March of Dimes says.
To view the multimedia release go to:
https://www.multivu.com/players/English/8189251-march-of-dimes-premature-birth-report-card-2017/
Inspire Medical Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Inspire Upper Airway Stimulation (UAS) therapy for use in a subset of patients with moderate to severe Obstructive Sleep Apnea (OSA) who are unable to use Continuous Positive Airway Pressure (CPAP). Inspire therapy is a fully implanted neurostimulation device, the first of its kind for sleep apnea, that provides an alternative treatment that is proven, convenient and easy to use.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7169651-fda-approves-inspire-upper-airway-stimulation-therapy-sleep-apnea
When a life-changing diagnosis brings moments of uneasiness, a glimmer of hope can make all the difference in bringing solace. As hope comes in many forms, Extended Stay America® hotels, the nation’s largest owner operated hotelier, announced today the launch of the brand’s latest initiative in their continued support for the fight against cancer – the “Give Hope” program. A natural evolution of Extended Stay America’s partnership with the American Cancer Society, the “Give Hope” program provides a platform to raise awareness and funds for pediatric cancer research.
To view the multimedia release go to:
https://www.multivu.com/players/English/8060751-extended-stay-america-give-hope-cancer-research/
The European Head and Neck Society (EHNS) and the Make Sense Campaign, today announced the launch of the Third Annual Head and Neck Cancer Awareness week (21–25 September). Through the pan-European Awareness Week, the EHNS and Make Sense Campaign promote education on head and neck cancer risk factors, disease prevention and disease signs and symptoms for both patients and healthcare professionals.
“Each year 350,000 people are diagnosed with head and neck cancer across Europe, and over half will not be alive after five years. However, if diagnosed and treated earlier, patients can have an 80 – 90% survival rate.” said Professor René Leemans, President of the EHNS and Professor and Chief of Otolaryngology – Head and Neck Surgery at VU University Medical Centre. “Through the Make Sense Campaign we are educating people about the early signs of the disease and encouraging them to seek professional help in a timely manner. Additionally, we are advocating for the best possible standards of patient care so that their outcomes can be optimised once they have been diagnosed with the disease.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7628151-support-head-neck-cancer-patients/
